Differences

This shows you the differences between two versions of the page.

--- documentation:oncology:meeting_notes_2017_oct-19 [2017/10/28 18:07] – rimma_belenkaya
+++ documentation:oncology:meeting_notes_2017_oct-19 [2017/10/30 15:17] (current) – rimma_belenkaya
@@ Line 1: / Line 1: @@
 {{:documentation:oncology:f-t-f_oncology_meeting.docx|Face-to-Face Oncology Meeting Notes}}
-Next steps
+**Next steps**
-I. Tasks to generate the minimal viable product
+**I. Tasks to generate the minimal viable product**
 .	Diagnosis
@@ Line 23: / Line 23: @@
 .	Staging
 Choose vocabulary
+???
 .	Treatments
 a.	Drugs
-•	Compare SEER drugs list with RxNorm cancer drug classes and decide which one should be used in the vocabulary. If SEER is more suitable, add SEER classification to the vocabulary.
+  * Compare SEER drugs list with RxNorm cancer drug classes and decide which one should be used in the vocabulary. If SEER is more suitable, add SEER classification to the vocabulary.
-•	Add SEER drug cocktails to the vocabulary (only ingredients, no other specifics) in EMR based on those combinations.
+  * Add SEER drug cocktails to the vocabulary (only ingredients, no other specifics) in EMR based on those combinations.
-•	Identify chemo regimens in EMR using SEER cocktails and validate with chemo orders when available
+  * Identify chemo regimens in EMR using SEER cocktails and validate with chemo orders when available
-•	Work on cancer Drug Era algorithm and modeling in CDM
+  * Work on cancer Drug Era algorithm and modeling in CDM
 b.	Overlay cancer registry treatment schema (first occurrence only) with EMR details to construct complete treatment regimen
 c.	Model representation of the treatment regimen (era) in the CDM
-II. Exploratory
-.	Discuss with IMO procedure mappings to SNOMED and classification of cancer cases.
-.	Explore commercial solutions that claim to identify cancer treatment regimens, recurrences, progression and compare the outcomes with our attempts to identify treatment regimens
-.	Invite Andrew Stewart and Mark Denise to present their efforts and results in mapping to CDM and additional modeling
-.	Find a geneticist and oncologist to identify cancer-relevant genomic areas
-.	Find  out if we can get cancer registry data from any of the “SEER” states
-III. Operational
+**II. Exploratory**
-.	Document challenges related to extending OHDSI infrastructure to support cancer research for NCI
+  - Discuss with IMO procedure mappings to SNOMED and classification of cancer cases.
+  - Explore commercial solutions that claim to identify cancer treatment regimens, recurrences, progression and compare the outcomes with our attempts to identify treatment regimens
+  - Invite Andrew Stewart and Mark Denise to present their efforts and results in mapping to CDM and additional modeling
+  - Find a geneticist and oncologist to identify cancer-relevant genomic areas
+  - Find  out if we can get cancer registry data from any of the “SEER” states
+**III. Operational**
+Document challenges related to extending OHDSI infrastructure to support cancer research for NCI